Latest Regenerative Medicine News

Page 2 of 8
Orthocell Limited has reported a record half-year revenue of $6.2 million, driven by accelerating sales of its regenerative medicine products and expanding global footprint. The company’s US commercial launch of Remplir™ is gaining momentum alongside new market entries in Canada, Hong Kong, and Europe.
Ada Torres
Ada Torres
24 Feb 2026
Cambium Bio has secured FDA clearance to begin Phase 3 dosing for its lead ophthalmology product, Elate Ocular®, alongside key global partnerships and a $2.4 million capital injection from a major shareholder.
Ada Torres
Ada Torres
20 Feb 2026
Orthocell has secured a $3 million R&D tax refund, lifting its cash reserves to nearly $50 million and reinforcing its financial strength as it pushes commercialisation of its nerve repair product Remplir™ across key global markets.
Ada Torres
Ada Torres
18 Feb 2026
Osteopore Limited has drawn down the second tranche of its redeemable convertible notes, raising A$500,000 as part of a broader A$20 million funding agreement with Advance Opportunities Fund. The funds are earmarked to support ongoing operations and future growth initiatives.
Ada Torres
Ada Torres
16 Feb 2026
Osteopore Limited has secured an exclusive three-year distribution deal with Medprin Biotech GmbH to broaden its presence in Latin America's craniofacial reconstruction market, tapping into a region poised for significant growth.
Ada Torres
Ada Torres
13 Feb 2026
Osteopore Limited has successfully raised the entire $5 million from the first tranche of its $20 million convertible notes issuance, securing funds to support ongoing operations and future growth.
Ada Torres
Ada Torres
6 Feb 2026
Cynata Therapeutics has successfully raised $1.2 million through an At-The-Market equity raise, issuing shares at a discount to support its ongoing clinical programs. This capital injection aims to bolster working capital as the company advances its proprietary stem cell therapies.
Ada Torres
Ada Torres
23 Jan 2026
Cambium Bio has strengthened its financial footing with a $0.6 million R&D tax refund and a $2.4 million strategic placement, setting the stage for pivotal Phase 3 clinical trials of its lead ophthalmology candidate.
Ada Torres
Ada Torres
23 Jan 2026
Osteopore Limited has secured an exclusive agreement with MontsMed Hong Kong to introduce its innovative 3D-printed orthopaedic implants into Hong Kong, positioning itself strategically within the Greater Bay Area’s burgeoning medical market.
Ada Torres
Ada Torres
22 Jan 2026
Mesoblast has received encouraging feedback from the FDA on its cell therapy rexlemestrocel-L, showing meaningful pain relief and potential opioid use reduction in chronic low back pain patients. The company’s ongoing Phase 3 trial aims to confirm these benefits and advance regulatory approval.
Ada Torres
Ada Torres
19 Jan 2026
Orthocell Limited has reported a record $3.2 million revenue for the December 2025 quarter, marking its seventh consecutive quarter of growth, fuelled by expanding sales of its nerve repair product Remplir in the US and other international markets.
Ada Torres
Ada Torres
19 Jan 2026
Osteopore Limited has inked an exclusive collaboration with Majeton to commercialise its cutting-edge 3D-printed bioresorbable implants across China, Hong Kong, and Macau, unlocking significant growth potential in the region.
Ada Torres
Ada Torres
16 Jan 2026